Q2 Earnings Estimate for Alphatec Issued By HC Wainwright

Alphatec Holdings, Inc. (NASDAQ:ATEC) – Equities research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of Alphatec in a research report issued to clients and investors on Wednesday, February 25th. HC Wainwright analyst S. Lee expects that the medical technology company will post earnings of $0.01 per share for the quarter. HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Alphatec’s FY2026 earnings at $0.09 EPS and FY2030 earnings at $1.13 EPS.

Several other equities research analysts have also recently issued reports on ATEC. Loop Capital set a $25.00 price objective on Alphatec in a report on Wednesday, December 10th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. TD Cowen restated a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Lake Street Capital reiterated a “buy” rating on shares of Alphatec in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating on shares of Alphatec in a research report on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus price target of $22.82.

Alphatec Stock Down 2.8%

ATEC stock opened at $13.62 on Monday. The company has a 50 day moving average price of $16.74 and a two-hundred day moving average price of $17.11. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06. The stock has a market capitalization of $2.06 billion, a P/E ratio of -14.34 and a beta of 1.02. Alphatec has a one year low of $8.81 and a one year high of $23.29.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $212.93 million for the quarter, compared to analysts’ expectations of $212.67 million. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.23) earnings per share.

Institutional Trading of Alphatec

Several large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC raised its position in Alphatec by 292.2% in the fourth quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock valued at $46,834,000 after purchasing an additional 1,658,349 shares during the period. Granite Investment Partners LLC grew its stake in shares of Alphatec by 320.6% in the second quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock valued at $19,102,000 after buying an additional 1,311,748 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in shares of Alphatec during the 4th quarter valued at about $27,051,000. Morgan Stanley raised its holdings in shares of Alphatec by 22.0% during the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock valued at $91,333,000 after buying an additional 784,191 shares during the period. Finally, Tudor Investment Corp ET AL lifted its position in Alphatec by 608.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock worth $13,093,000 after acquiring an additional 773,367 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP Craig E. Hunsaker sold 37,358 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $14.71, for a total transaction of $549,536.18. Following the completion of the sale, the executive vice president directly owned 1,173,025 shares in the company, valued at $17,255,197.75. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David R. Pelizzon sold 250,000 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the completion of the sale, the director directly owned 10,395,045 shares of the company’s stock, valued at $204,366,584.70. The trade was a 2.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 1,336,125 shares of company stock worth $27,174,878. Company insiders own 22.80% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.